M1 Kliniken AG

  • ISIN: DE000A0STSQ8
  • Land: Deutschland

Nachricht vom 03.06.2019 | 09:30

M1 Kliniken AG expands its range of medical cosmetic products: Medium-term segment sales in the lower double-digit million euro range possible

DGAP-News: M1 Kliniken AG / Key word(s): Product Launch/Expansion

03.06.2019 / 09:30
The issuer is solely responsible for the content of this announcement.

M1 Kliniken AG expands its range of medical cosmetic products: Medium-term segment sales in the lower double-digit million euro range possible

- M1 SELECT with focus on highly effective skin care products based on hyaluronic acid

- Skin care market in Germany alone worth 3.2 billion euros

- Distribution via own locations, the online shop and B2B

Berlin, 03.06.2019 - M1 Kliniken AG (ISIN: DE000A0STSQ8) is driving growth in the field of medical cosmetic products. Under its own brand M1 SELECT, the beauty medicine specialist has been offering a selected range of high-quality active cosmetics with a focus on skin and facial care since December 2017. Now the range is being expanded with innovative new products, developed jointly with M1 dermatology specialists: from antioxidant serum to intensive sun protection to moisture boosters with hyaluronic acid complex in highly concentrated form. M1 is thus opening up an additional growth market. In 2018, consumers spent around 13.8 billion euros on their beauty (source: IKW). Skin and facial care products account for the largest share with 3.2 billion euros. In the medium term, M1 sees sales potential for medical cosmetic products in the lower double-digit million euro range. By way of comparison: in 2018, segment sales were in the six-digit euro range.

"At M1 SELECT, high-quality care meets medical know-how at best prices and made in Germany. We are delighted that our own products have already been well received in the first year and that we can now begin the rollout of a broader range of products," says Patrick Brenske, CEO of M1 Kliniken AG. "Because beauty doesn't have to be expensive. This motto applies to our entire brand family with which we want to develop M1 into the number 1 in beauty in Europe".

In distribution, the Group benefits from its market leadership in the field of plastic and aesthetic treatments. It now operates 24 M1 Med Beauty specialist centres for beauty treatments throughout Germany and the M1 Schlossklinik für Plastische und Ästhetische Chirurgie in Berlin. In addition, M1 started its internationalisation with the specialist centre in Vienna at the end of 2018. The products can be purchased at all locations. In addition, the products are distributed via the company's own online shop (https://m1-select.de) and as B2B to cosmetic studios. For the future, cooperation with retail partners - such as a drugstore or perfumery chain - is an option.

About M1 Kliniken AG

M1 Kliniken AG is the leading provider of beauty medicine health services in Germany. In the aesthetic and surgical field, the group offers products and services of the highest quality. Under the brands M1 Med Beauty, M1 Laser and M1 Dental, beauty medical treatments are currently offered at more than 25 locations. The M1 Schlossklinik for plastic and aesthetic surgery in Berlin, with six operating theatres and 35 beds, is one of the largest and most modern facilities of its kind in Europe. In addition, the Group markets high-quality products to private customers, doctors, pharmacies and wholesalers under the M1 Select and M1 Aesthetics brands. www.m1-kliniken.de


M1 Kliniken AG
Grünauer Straße 5
12557 Berlin
Phone: +49 (0)30 347 47 44 14
E-mail: ir@m1-kliniken.de

03.06.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

Event im Fokus

Fachkonferenz Beteiligungsgesellschaften, 15.07.2020

Fachkonferenz Consumer / Leisure, 16.07.2020

Die Konferenzen finden aufgrund der aktuellen Situation nicht in den Räumen der Börse München statt, sondern als Online-Konferenz.

News im Fokus

Covestro AG: Vorläufiges EBITDA von EUR 124 Mio. in Q2 2020 liegt über Markterwartung

09. Juli 2020, 11:56

Aktuelle Research-Studie

Original-Research: PAION AG (von First Berlin Equity Research GmbH): Kaufen PAION AG

09. Juli 2020